Sep 26 2011
iCo Therapeutics Inc. (TSXV: ICO) today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema (DME).
DME is a major complication of diabetes and a leading cause of blindness in adults. In DME, leakage of fluid from the blood vessels in the eye causes the retina to swell, resulting in blurring and loss of vision.
"We are delighted to be collaborating with JDRF on such an important project," stated Andrew Rae, President & CEO of iCo Therapeutics. "JDRF is dedicated to finding better treatments and cures for diabetes and its complications, including DME, and has played a very important patient advocacy role which cannot be underestimated. We look forward to working with JDRF to explore iCo-007's potential in DME."
"JDRF is committed to supporting research that accelerates the delivery of therapeutics that improves the quality of life for people living with diabetes and its complications," said Aaron Kowalski, Ph.D., Assistant Vice President of Treatment Therapies for JDRF. "As part of this commitment, we have made retinopathy a high priority research emphasis area, and this includes working with partners such as iCo on clinical trials focused on slowing or halting the progression of diabetic eye disease."
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy